Improved Survival Benefit of Autologous Dendritic Cell-Based Vaccine for Hormone Refractory Prostate Cancer: A Retrospective Subset Analysis of the D9901 Trial

Clinical Prostate Cancer

Volumn 2, Issue 4, 2004, Pages 212-

  Price, Nancy ^a   Sartor, Oliver ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENDRITIC CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTE; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 8744241964     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1540-0352(11)70047-6     Document Type: Note

References (4)

1. Small EJ, Rini B, Higano C, et al. A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa). Proc Am Soc Clin Oncol 2003; 22:382 (Abstract#1534).
2. Schellhammer P, Small EJ, Higano CS, et al. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for hormone refractory prostate cancer: a phase III randomized, double blind, placebo controlled trial. Proc Am Soc Clin Oncol 2002; 21:183a (Abstract #731).
3. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-3903.
4. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for patients with hormone-refractory prostate cancer with a Gleason score ≤ 7. Clinical Prostate Cancer 2003; 2:81-83.